SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

01 Nov 2023 Evaluate
The September 2023 quarter revenue stood at Rs. 1713.15 millions, up 23.38% as compared to Rs. 1388.49 millions during the corresponding quarter last year.The company has announced a 33.18% increase in its profits to Rs . 338.91  millions for the  quarter ended September 2023 compared to Rs. 254.47 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 529.22 millions compared to 408.66 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 1713.15 1388.49 23.38 2803.07 2861.29 -2.03 5983.40 6363.57 -5.97
Other Income 106.14 142.31 -25.42 171.41 328.65 -47.84 507.66 326.28 55.59
PBIDT 529.22 408.66 29.50 705.00 786.47 -10.36 1409.21 1418.26 -0.64
Interest 11.78 18.39 -35.94 24.87 38.81 -35.92 100.57 43.24 132.59
PBDT 517.44 390.27 32.59 680.13 747.66 -9.03 1308.64 1402.47 -6.69
Depreciation 56.78 37.35 52.02 110.42 74.09 49.03 151.73 138.47 9.58
PBT 460.66 352.92 30.53 569.71 673.57 -15.42 1156.91 1264.00 -8.47
TAX 121.75 98.45 23.67 155.84 172.66 -9.74 302.14 337.36 -10.44
Deferred Tax 1.29 7.55 -82.91 8.29 -4.70 -276.38 -42.10 7.68 -648.18
PAT 338.91 254.47 33.18 413.87 500.91 -17.38 854.77 926.64 -7.76
Equity 104.40 103.89 0.49 104.40 103.89 0.49 104.15 103.68 0.45
PBIDTM(%) 30.89 29.43 4.96 25.15 27.49 -8.50 23.55 22.29 5.68

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×